Business Wire

NOW-HEALTH-INTERNATIONAL

7.6.2021 10:02:06 CEST | Business Wire | Press release

Share
Now Health International Teams up With Starr Insurance Companies

Now Health International Group, a leading International Private Medical Insurance (IPMI) provider, has announced a new program with Starr Insurance Companies, a leading global insurance company, to drive forward ambitious growth plans in Europe.

This mutually beneficial relationship combines Now Health International’s global presence and expertise in providing high quality international health insurance solutions and state of the art digital tools, including the recently launched Mobile Pass innovation, with Starr’s long-standing global knowledge and ability to deliver customised solutions across Europe through a specialised team of professionals dedicated to offering the best service to its customers.

Under the new agreement, as of 1st March 2021, Starr Insurance Companies will insure all new and renewing business across Europe. Now Health International will continue to administer the international health insurance plans, including claims handling and customer service support. All members will also continue to benefit from access to Now Health International’s award-winning digital tools.

Zahir Sharif, Managing Director, Now Health International said, “At Now Health International we are committed to further building our presence in Europe and have ambitions to expand into new markets across the region. Starr Insurance Companies, with over 100-years of heritage, expertise and existing presence across global markets, is a well-placed partner to help us achieve this goal.”

Now Health International will continue to offer its existing products to members across Europe under the new partnership, including its flagship, benefit-rich WorldCare product, and its more affordable SimpleCare product for those looking for essential health cover. There will be no changes to plan benefits, pricing, or the customer service experience as a result of this arrangement.

The new program replaces Now Health International’s previous relationship with AXA PPP Healthcare. To ensure a smooth transition process for existing members, a runoff period will be deployed until 31st December 2021, seamlessly transitioning members to the new arrangement with Starr Insurance Companies at their next plan renewal.

Michel Faucher, Chief Commercial Officer, Now Health International added, “We are very excited about our new relationship and the opportunities it presents for us in the long term. I also want to reassure our members and partners that there will be complete continuity under the new arrangements, with the same market-leading plans and benefits, high standards of service, and state of the art digital tools our European customer base have come to expect.”

Santiago Mora, Head of International Accident & Health for Starr, said, “We’re excited to be the insurance provider for Now Health International, one of the fastest growing providers of medical insurance solutions for global expatriates.”

-ENDS-

Notes to Editors: About Now Health International Group

The Now Health International Group consists of Now Health International and Best Doctors Insurance. Now Health International is one of the fastest growing providers of International Private Medical Insurance (IPMI) solutions for Global Expatriates, High-Net-Worth individuals and Companies. Now Health has offices in the UK, Malta, UAE, China, Hong Kong, Singapore and Indonesia. Best Doctors Insurance is a Bermuda/ Miami based major medical insurance provider with offices in the US, Canada and Ecuador and distribution throughout Central and Latin America, the Caribbean and Canada.

The combined business is a global top tier specialist IPMI provider, with complementary products, distribution and geographies. The operation spans four continents, with 11 sales &/or service offices, 125,000+ members, 370+ employees and 5,000+ distribution partners.

www.now-health.com

www.bestdoctorsinsurance.com

Notes to Editors: About Starr Insurance Companies

Starr Insurance Companies (or Starr) is a marketing name for the operating insurance and travel assistance companies and subsidiaries of Starr International Company, Inc. and for the investment business of C. V. Starr & Co., Inc. and its subsidiaries. Starr is a leading insurance and investment organization with a presence on six continents; through its operating insurance companies, Starr provides property, casualty, and accident and health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance. Starr’s insurance company subsidiaries domiciled in the U.S., Bermuda, China, Hong Kong, Singapore, U.K. and Malta each have an A.M. Best rating of “A” (Excellent). Starr’s Lloyd’s syndicate has a Standard & Poor’s rating of “A+” (Strong).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye